A tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.
A collaborative project initiated by the ESMO Precision Medicine Working Group aims to optimise tumour-agnostic drug development. Through assessment of different scenarios in terms of minimum objective response rate, number of tumour types investigated, and number of evaluable patients per tumour type, a screening tool for tumour-agnostic potential has been developed.
Based on the therapeutic effect obtained by targeting a driver molecular aberration across tumours and its modulation by tumour-specific biology, a taxonomy for classifying molecularly guided treatment options was proposed with the following three categories: tumour-agnostic, tumour-modulated, and tumour-restricted. Furthermore, a framework for tumour-agnostic drug development was conceptualised.